Merck/Ariad Form Billion-Dollar Collaboration To Develop mTOR Inhibitor For Cancers
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s commitment to using biomarkers, bioinformatics and diagnostics in cancer drug development was key to the deal, Ariad CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap
With positive signs for its stable of cancer drugs, including an imminent filing for the sarcoma candidate ridaforolimus, Ariad Pharmaceuticals Inc. is nearing the turning point from a development to a commercial company.
Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap
With positive signs for its stable of cancer drugs, including an imminent filing for the sarcoma candidate ridaforolimus, Ariad Pharmaceuticals Inc. is nearing the turning point from a development to a commercial company.
Ariad Opts-in To Co-Promote mTOR With Merck
The biotech takes advantage of the Big Pharma's financial wherewithal and regulatory/market expertise to build out its own commercial infrastructure.